29 April 2016: The CMA has provisionally found that Celesio AG’s anticipated acquisition of Sainsbury’s pharmacy business could lead to a substantial lessening of competition in 13 areas in England and Wales.
The publication of the evidence of any party on the CMA’s webpages does not indicate in any way endorsement by the CMA of the views expressed in the evidence or acceptance of that evidence. Publication in this way is designed to assist public understanding of the issues.
Responses to provisional findings and notice of possible remedies
26 January 2016: The issues statement sets out the scope of the investigation. It outlines initial theories on what might be adversely affecting competition, but it does not set out findings or conclusions.
Stephen Oram holds a small number of ordinary shares in GlaxoSmithKline and Shire. The CMA is satisfied that this matter will not prejudice the ability of the inquiry group to discharge its functions in an independent and impartial manner.
Terms of reference
29 December 2015: The CMA has referred the anticipated acquisition by Celesio AG of Sainsbury’s Supermarkets Limited UK Pharmacy Business.